We explored the possibility that pulsed antigen-presenting cells (APC) 
Introduction
Animal models provided unique experimental opportunities to investigate new perspectives on immunointervention in autoaggressive immune reactions. Over the past decade, collagen-induced arthritis (CIA), which mimics the clinical symptoms and histopathological changes observed in rheumatoid arthritis, has been extensively used to propose a variety of approaches for the immunotherapy of autoimmune arthritides. CIA is initiated in susceptible strains of mice by immunization with native type II collagen (CII) in adjuvant. 1 Considerable data implicate CD4 + T cells expressing the Th1 phenotype in the pathogenesis of CIA. [2] [3] [4] [5] [6] Conversely, several lines of evidence assign to Th2 lymphocytes a protective role in CIA via the production of anti-inflammatory cytokines. Thus, administration of Th2-type cytokines such as IL-4, IL-10 and IL-13, was shown to reduce the incidence and the severity of clinical arthritis. [7] [8] [9] [10] [11] In our laboratory, the use of cell-based therapy for systemic delivery of Th2 cytokines provided a powerful therapeutic approach in CIA. Indeed, inoculation of Chinese hamster ovary (CHO) fibroblasts engineered to pro- duce high levels of murine IL-4 or IL-13 into CII-immunized mice, markedly inhibited the experimental disease. 7 Interestingly, encapsulation of the transduced CHO cells into permeable hollow fibers prior to in vivo transfer further ameliorated the beneficial effect of the cytokines. 12 Based on the potential capacity of Fas ligand to provoke apoptosis of pathogenic Fas + cells, we have co-transfected the CHO cells with plasmid DNA encoding for IL-4 and Fas ligand. We provided evidence that Fas ligand expression on IL-4-producing CHO cells potentiated the therapeutic effect of the cytokine in CIA and suggested that Fas-mediated apoptosis of neutrophils contributed to down-regulation of inflammation. 13 However, the inherent problems of xenogeneic vector cells limit the usefulness of such strategies and therefore, prompted us to utilize genetically modified murine cells as cellular vectors. In the recent past, approaches using antigen-specific T cells to introduce directed immune therapeutics in animals suffering from autoimmune diseases was described as an interesting alternative to that proposed previously.
groups. When the same dose of cells was transferred at disease onset, a moderate beneficial effect was observed. Whatever the APC inoculated, the beneficial effect did not rely upon an IL-4-driven shift towards Th2 phenotype. Systemic administration of fluorescent dye labeled macrophages to arthritic mice has shown that some of these cells rapidly migrate to joints. Moreover, IL-4 transfected macrophages retained their potent capacity to present CII peptides to T cells. These findings validate the use of CII peptideloaded engineered APC as therapeutic vector cells in CIA and allow consideration of this strategy for the administration of various anti-inflammatory proteins. Gene Therapy (2001)
14 Indeed, several groups reported the successful localization of the transgene in the inflamed tissues associated with reversion of pathological manifestations in different murine models of autoimmunity, including CIA, by injection of antigen-specific T cells transduced with retroviral vectors encoding for IL-4, 15 IL-10 16, 17 , TGF-␤ 18 or IL-12 antagonist. 19 Most recent strategies pointed to immunosuppressive capacities of Gene Therapy antigen-presenting cells (APC) engineered to express regulatory proteins. 20 For example, APC expressing high levels of Fas ligand down-modulated pathological signs in a murine model of chronic inflammatory disease. 21 In the current study, we hypothesized that the antigenprocessing capacity and migratory properties of various APC may represent an appropriate endogenous system for site-specific delivery of therapeutic transgene proteins during autoimmune diseases. Since we and others have previously reported that gene therapy with the Th2 cytokine IL-4 inhibits animal models of rheumatoid arthritis including CIA, 7, [22] [23] [24] [25] we explored the ability of APC transduced with murine IL-4 gene and pulsed with CII to interfere with the pathological process developing in murine CIA. Our hypothesis was tested by using two types of APC engineered to secrete this cytokine: B cells which were reported to elicit preferentially a Th2 response 26 and macrophages that can migrate to inflamed tissues and that we found to be the most potent APC in the response towards CII. 27 
Results

Inoculation of CII-pulsed B cell lines protects against CIA
We investigated the potential advantage of IL-4 producing APC loaded with CII at down-regulating CIA using as vector cells a hybridoma B cell clone (named M12.C10) established in our laboratory. 27 These hybrid APC express high levels of I-A q molecules and low levels of surface Ig and are potent presenters of CII peptides to specific T cells. 28 Thus, DBA/1 mice were injected, on days Ϫ2 and +7 related to CII priming, with M12.C10 cells transfected with murine IL-4 cDNA and preincubated with or without cyanogen bromide-cleaved CII (CB-CII). Monitoring of clinical course of arthritis revealed a progressively increasing inflammatory response in the control group given unmanipulated M12.C10 cells from day +23 to day +42 after CII-immunization, then reaching a plateau. Administration of IL-4 producing M12.C10 cells reduced the severity of CIA. Such effect was still more pronounced when transfected M12.C10 cells were pulsed with the antigen before their injection, thus resulting in significantly lower arthritis severity along the clinical course of CIA and delayed disease onset ( Figure 1 and Table 1 ). Notably, CII-loaded cells were equally effective in down-regulating CIA, whether or not they were transfected with IL-4 gene. Based on previous studies demonstrating that the peptide of bovine CII (CII-p256-270) was immunodominant, 29 we tested whether inoculation of M12.C10 cells preincubated with this peptide will also affect the outcome of CIA. Indeed, treatment with CII-p256-270-pulsed M12.C10 cells down-regulated the development of arthritis, but the effect was modest compared with that observed when APC presented peptides derived from the entire molecule of CII (Table 1) .
Lack of Th2-biased immune response upon transfer of M12.C10 cells transfected with IL-4 gene and presenting CII peptides
Based on the well-documented role of IL-4 in deviating the immune response towards a Th2 profile and on a previous report that antigenic presentation by B cells also favors Th2 differentiation, 26 we analyzed the phenotype of CII-specific responses upon treatment with engineered B cells. For that purpose, three mice from each treatment group were killed on day +12 after immunization and their lymph node cells used for study of CII-specific T and B cell responses. Table 1 shows that none of the groups considered exhibited significantly different levels of either antigen-induced proliferation, IFN-␥ production in vitro or humoral response to CII measured on day +30. Indeed, CII-induced IFN-␥ levels were elevated in all the groups even those treated with IL-4 transduced cells (Table 1 ) and conversely, IL-4 was not detectable in the culture supernatants regardless of the treatment administered (not shown). Interestingly, we failed to note relative variations in the levels of CII-specific IgG isotypes upon either treatment (not shown) further strengthening the lack of early Th2 shift in our experimental system.
Production and characterization of DBA/1 macrophages engineered to express IL-4
To explore the ability of other IL-4 expressing APC to influence the development of CIA, bone marrow-derived macrophages from DBA/1 mice were generated and transfected with murine IL-4 cDNA or empty vector as control (Figure 2a) . Transfection procedures were optimized to yield about 50% efficiency as shown with the GFP gene marker. Macrophages engineered to produce IL-4 expressed similar levels of MHC class II (I-A q ) and costimulatory (B7.1, B7.2) molecules than naive macrophages (not shown). They were also fully competent to present CII peptides to a specific T cell hybridoma, though with a lower magnitude than nontransfected macrophages or empty vector-transduced controls ( Figure 2b ).
Transfer of IL-4 producing macrophages pulsed with CII ameliorates CIA
We next assessed the effect of treatment with genetically modified macrophages on the development of arthritis. Circulating levels of CII-specific IgG expressed as mean ± s.e.m. arbitrary units (AU) were determined on day +30 post-priming by ELISA.
In a first experiment, DBA/1 mice were given two i.p. injections around the day of CII-priming with varying doses of syngeneic macrophages transfected with murine IL-4 cDNA and loaded (Mp/IL-4+CII) or not (Mp/IL-4) with CII. Figure 3a shows that the disease progressed to severe signs of inflammation (characterized by redness and swelling involving multiple limbs) in the control group, as well as in the groups treated with the lower (10 4 cells/dose) and the higher (10 6 cells/dose) Mp/IL-4 concentrations. Pulse of transfected macrophages with CII before the transfer of 10 6 cells resulted in only a weakly impaired severity of CIA. When mice received 2 × 10 5 Mp/IL-4 per dose, arthritis manifestations were milder but still not significantly different to controls and the presence of CII peptides at the cell surface further reduced and delayed the clinical signs of arthritis ( Figure  3a) . In a second experiment using the optimal dose of 2 × 10 5 cells administered according to the same preventive protocol, we confirmed the beneficial effect of Mp/IL-4+CII on CIA course since this treatment induced a prolonged amelioration of arthritis compared with all other groups (Figure 3b ). To explore the mechanisms underlying the effects of preventive treatment with CII-loaded and IL-4-transfected macrophages, we have analyzed the CII-specific responses in mice from the second experiment. In all the treatment groups considered, lymph node cells collected 10 days after priming with CII and stimulated with the immunizing antigen exhibited high proliferative T cell responses and IFN-␥ production in the culture supernatants, but no IL-4 could be detected although the cells were fully competent to produce this cytokine in response to ConA (Table 2 ). In addition, the circulating levels of total IgG or IgG1 and IgG2a isotypes reacting to CII did not differ significantly between the groups. These findings indicate that the pathogenic Th1 response has not deviated towards a Th2 profile, at least during the early phases of arthritis induction, in the mice improved by the preventive treatment with Mp/IL-4+CII.
Gene Therapy
Syngeneic macrophages administered systemically migrate into the joints of arthritic mice
To determine whether macrophages could exert a local effect in the affected joints, the in vivo migration of fluorescent dye-labeled macrophages was examined. Arthritic DBA/1 mice were injected (i.v.) with fluorescent cells and at different times after cell transfer the synovial tissue from knees was collected, enzymatically digested and subjected to flow cytometry analysis. Six hours following inoculation of the cells, macrophages had not yet migrated into the synovium. Conversely, after 15 h, they were detected in the majority of the joints observed (12 of 18) and were still present at 24 h (Figure 4 ). In contrast, the fluorescent cells were barely found in the lung or the liver.
Effect of IL-4 producing macrophage transfer on the flare-up of arthritis
The migratory properties of macrophages and the amelioration of CIA upon preventive inoculation of IL-4 genetransduced macrophages prompted us to evaluate whether the same treatment was efficient in blocking the progression of established disease. Thus, immunized DBA/1 mice were given two i.p. injections of 2 × 10 5 manipulated macrophages pulsed or not with CII at onset of clinical arthritis (on days 34 and 37 after immunization). Progression of arthritis severity was then monitored in each group. Although adoptive transfer of macrophages producing IL-4 and/or presenting CII peptides tended to reduce the progression of arthritis compared with controls treated with mock-transfected and nonpulsed APC, the difference was modest and not significant ( Figure 5 ).
Discussion
The present study reports for the first time that in vivo transfer of CII-loaded B cells and macrophages, genetically engineered to deliver an anti-inflammatory mol- ecule such as IL-4, is effective to reduce the severity of CIA. We surmised that, used as vector cells, syngeneic APC pulsed with the immunizing antigen, thereby presenting the arthritogenic peptide(s) will offer the potential for suppressing CIA by targeting the ongoing autoimmune response and producing in situ the antiinflammatory protein.
To address this possibility, the first type of APC we utilized as IL-4-producing cells was a B cell hybridoma, M12.C10, that we selected previously for its potent capacity to present CII peptides to specific T cells. 27 Indeed, treatment around the immunization with CIIpulsed M12.C10 suppressed the clinical signs of arthritis regardless of their IL-4 expression while control animals given intact M12.C10 cells exhibited severe disease. Interestingly, IL-4 delivered by nonpulsed APC displayed an 
circles). Macrophages were loaded (closed symbols) or not (open symbols) with CII before inoculation. Controls received PBS (crosses). Data are means of six mice per group.
intermediate effect characterized by the development of mild arthritis. Thus, the infusion of B cells presenting CII peptides at initiation of anti-CII response in immunized mice prevented the occurrence of autoimmune disease. Our findings also reveal that bone marrow-derived macrophages are suitable vector APC for site-directed immunotherapy of CIA as adoptive transfer of IL-4 transfected macrophages using a preventive protocol, was able to significantly down-regulate CIA provided that they presented CII peptides. During the process of our work, two groups have conducted studies showing that dendritic cells genetically modified to express IL-4 inhibit CIA, we therefore extended their conclusions to other types of professional APC. 30, 31 However, in contrast to our work, the dendritic cells were not pulsed with CII before transfer.
The numbers of macrophages infused seems to be a critical factor in our strategy. The lack of effect upon treatment with low doses (10 4 macrophages) of cells may rely on the insufficient amount of IL-4 delivered for promoting the suppression of clinical symptoms. On the other hand, the reason why high doses (10 6 macrophages) of cells failed to alter the CIA course is less clear and requires further investigations. The dose of IL-4 transduced macrophages loaded with CII which protected the mice when injected at the time of immunization moderately down-regulated arthritis severity when inoculated at clinical onset. These findings could indicate that the inhibitory effect mediated by the manipulated macrophages is mainly directed against the afferent arm of the autoimmune response, affecting the priming of CII-specific T cells, while it is not effective in reverting joint inflammation in CIA. 10 Such explanation is unlikely when considering the benefits of late treatment with IL-4 in CIA using a variety of therapeutic strategies. Actually, arthritis progression was shown to be blocked by administration of IL-4 gene-modified fibroblasts, 32 as well as by gene transfer. This last strategy was achieved by injection DBA/1 mice were immunized with CII in CFA and treated (2 × 10 5 cells on days Ϫ2 and +2 related to CII-priming) with syngeneic macrophages transfected with IL-4 cDNA (Mp/IL-4) or empty vector (Mp/0) that were previously loaded (or not) with CII. Arthritis evaluation and specific immune response monitoring were conducted as described in the legend to Table 1 , except that T cell responses and anti-CII IgG were determined on days +10 and +35 post-priming, respectively.
Figure 4 In vivo migration of macrophages into the joints of arthritic mice. Fluorescent dye-labeled macrophages were injected i.v. to immunized mice with clinical signs of arthritis and the percentages of fluorescent cells present into the joints, the lung or the liver were evaluated at varying times after transfer (see Materials and methods). Data are expressed as incidence (% and n) of joints containing fluorescent cell numbers over background levels.
of either viral vectors expressing IL-4 22, 23, 33 or naked DNA plasmids into arthritic mice (our unpublished observations). Thus, it is plausible that higher amounts of regulatory cytokines are required to block the ongoing flare up of CIA than to control the initiation of immune response.
In the current study, we showed that antigen-pulsed APC (but not unloaded cells) genetically altered with nonviral vectors to secrete IL-4 provide an efficient strategy for blocking clinical manifestations of CIA. In contrast to macrophages, M12.C10 B cells were fully competent to prevent arthritis induction, even when they were not transfected with IL-4 gene. These findings raise the question of the respective roles of IL-4 and CII peptides in our experimental system. Because IL-4 is a potent inducer of Th2 responses, it was possible that adoptive transfer of CII-pulsed APC transfected with IL-4 cDNA at the time of immunization suppressed CIA by early Gene Therapy shifting the balance of Th1/Th2 cells and skewing the production of anti-CII IgG isotypes. Analysis of the Th1-and Th2-derived cytokine profiles after antigenic stimulation of lymph node cells 10 days post-priming did not show any deviation towards a Th2 response in the IL-4-treated groups, nor did it reveal impairment of the predominant Th1 response driven by CII in CFA. Furthermore, the reduction in the levels of anti-CII antibodies noted in the groups given engineered APC was not associated with a switch in IgG isotypes. Such conclusions apply for both vector APC used, B cells and macrophages. In contrast, IL-4 producing dendritic cells, which were very recently reported to block CIA development, reduce the splenic Th1 response 1 or 2 weeks after cell transfer. 30, 31 Thus, the mechanisms through which systemic administration of IL-4 could ameliorate arthritis symptoms in our experimental system are unlikely to be dependent on early generation of CII-specific pure Th2 cells with protective properties. Whether such immunoregulatory cells arise later in the periphery 6 or in the joints remains to be elucidated. Conceivably, IL-4 may exert its suppressive activity by affecting directly macrophage pro-inflammatory functions. There is ample in vitro and in vivo evidence that IL-4 is an important downregulator of TNF-␣ and IL-1␤ production by macrophages. We have previously reported that IL-4 delivered by transfected CHO cells strongly reduced mRNA expression of these two monokines in the spleens of treated mice undergoing CIA, as well as in the model of TNF-␣ transgenic mice that spontaneously develop arthritic disease. 7, 24 Similar conclusions that anti-arthritogenic effects of IL-4 were mediated by targeting the macrophage lineage, thereby preventing cartilage/bone destruction in the affected joint were also reached in other studies. 9, 10, 25 The fact that presentation of CII peptides by the APC was a crucial factor for arthritis protection is suggestive of evidence that the APC-presenting CII peptides had encountered specific T cells. Interestingly, the weaker efficiency of B cells pulsed with the immunodominant peptide of CII compared with B cells carrying all the peptides processed from the entire molecule indicate that several CII-specific T cell clones were involved in the tolerance induction. The ensuing mechanisms of protection may implicate the stimulation of specific regulatory CD4 + T cells, as already described in various animal models of inflammation. 34 Recently, a novel mechanism of regulatory T cell-mediated, antigen-specific suppression was reported which identified the regulatory T cells as double-negative cells possessing a unique combination of cell surface markers and array of cytokines. 35 Because these cells were shown to inhibit the function of pathogenic T cells carrying the same T cell receptor specificity, this mechanism could be involved in the protection mediated by M12.C10 cells presenting the CII-p256-270.
Taken together, our data suggest that pulsed macrophages or B cells are promising tools for specific immunotherapy of autoimmunity based on their ability to target the autoimmune response. 20 CII-loaded B cells were proven to exert potent suppressive effects on clinical arthritis independently of IL-4 production. On the other hand, beneficial effects using macrophages required both antigen presentation and genetic modifications, suggesting that, once they had migrated to the affected joints, these manipulated APC acted via specific interactions with T cells and local delivery of the anti-inflammatory cytokine. We suggest that our approach which allows site-directed combined therapy using immunosuppressive agents will be fruitful and that efforts to identify antigens involved during the course of human autoimmune diseases should be intensified.
Materials and methods
Expression vectors
The pcDNA3.1 plasmid containing IL-4 was obtained by subcloning the BglII fragment of the Tag IL-4 (gift from G Richter, Max Planck Institute, Berlin, Germany) encoding for the mouse IL-4 into the BamHI site of the pcDNA3.1 expression vector (Invitrogen, Leck, The Netherlands). After amplification, the plasmid was purified by affinity chromatography using EndoFree Plasmid Maxi Kit (Qiagen, Courtaboeuf, France) according to the manufacturer's recommendations and stored at 1 mg/ml in sterile water.
Generation of antigen-presenting cells
The hybridoma B cell clone M12.C10 (H-2 q/d ) was obtained by fusion between the murine B lymphoma cell line M12 and CII-primed DBA/1 spleen cells as described previously in detail. 27 Efficient presentation of CII by these APC requires prior cleavage of native CII by cyanogen bromide (CB-CII). 28 Macrophages were generated from DBA/1 bone marrow progenitors. Cells were flushed from femurs, washed and cultured for 7 days in 24-well plates in RPMI 1640 in the presence of rat GM-CSF-containing supernatants (25 ng/ml). After washing, adherent cells were transfected and incubated for 24 h. Adherent macrophages were then pulsed with antigen before being collected using lidocain (Sigma, Saint Quentin Fallavier, France; 4 mg/ml).
Gene transfection of APC M12.C10 cells and bone marrow derived macrophages were engineered to produce murine IL-4. Cell transfections with pcDNA3.1-IL-4 vector (or empty control vector) were performed using LipofectAMINE (Gibco-BRL, Cergy Pontoise, France) or Effectene (Qiagen, DNA-:Effectene ratio of 1:25) reagents according to the manufacturer's recommendations for M12.C10 cells and macrophages, respectively. Transduced M12.C10 cells were then cultured in the presence of G418 to establish stably transfected cell lines. Transduced macrophages were further incubated in culture medium for 24 h before use. Transfection efficiency of macrophages was of 50% as quantified by introducing the reporter gene GFP and determining the percentages of GFP + cells by flow cytometry. In vitro IL-4 production by 10 6 engineered APC during a 24-h period, measured by ELISA was 1.5 ng/ml and 250 pg/ml for M12.C10 cells and macrophages, respectively.
Induction and assessment of arthritides
Male DBA/1 (H-2 q ) mice were purchased from Harlan (Bicester, UK) and were used at 7-10 weeks of age. Immunization with bovine native CII (100 g emulsified in CFA, i.d.), boost with CII (100 g in IFA) on day +21 and blind evaluation of arthritis were performed as previously described in detail. 36 Clinical scores of each joint (graded 0 to 4) were summed to yield the arthritic score and the severity of CIA was expressed both as the mean score observed on a given day and as the mean of the maximal arthritic score reached by each mouse during the clinical course of the disease. In curative treatment protocols, the results were expressed as means of individual net scores calculated by subtracting arthritic scores evaluated on the last day of treatment.
Treatment with IL-4-engineered APC
IL-4 gene transduced and control APC were (or not) pulsed with the antigen (native CII, CB-CII, or CII-p256-270 synthetic peptide) at 20 g/ml for 4 h at 37°C before being injected into mice. Treatment consisted of two i.p. injections of either irradiated (5000 rad) IL-4-expressing M12.C10 hybrids (10 6 cells per dose) or nonirradiated syngeneic macrophages (10 4 to 10 6 cells per dose) administered around the moment of CII priming as indicated in the text. After treatment, each cage contained a mixture (in equal numbers) of mice from all the treatment groups and CIA was scored by an observer blind to the experimental procedure.
Collagen-specific immune responses DBA/1 mice were immunized with CII in CFA in the footpads and the afferent lymph nodes were collected 10-12 days later. T cell proliferative responses against bovine native CII were conducted as previously described. 37 Briefly, dissociated cells were cultured in the presence of CII (40 g/ml) or Concanavalin A (Con A, 5 g/ml) for 72 h at 37°C. Cell proliferation was determined by pulsing the cells with 3 H-thymidine (1 Ci/well) for the last 16-18 h of culture and measuring the radioactivity incorporated in the cells by liquid scintillation counting. Quantification of cytokines was performed in 48-h culture supernatants by ELISA using the following capture/biotinylated-revealing mAb pairs: R46A2/ XMG1.2 for IFN-␥ and BVD4-D11/BVD6-24G2 for IL-4. Absorption values were converted into concentrations using the respective recombinant mouse cytokines as standards. Anti-CII antibody levels were tested in individual sera (collected on days 30-35 post-priming) for total IgG, IgG1 and IgG2a directed to bovine native CII using a standard ELISA. 37, 38 RNA extraction and RT-PCR Total RNA extraction was performed by guanidium isothiocyanate-phenol procedure and then RT-PCR was achieved by a standard two-step procedure. 7 Primers for murine IL-4 (sense: 5'-CGAAGAACACCACAGA-GAGTGAGCT-3' and antisense: 5'-GACTCATTCATGGT GCAGCTTATCG-3') and for murine ␤-actin (sens: 5'-TGGAATCCTGTGGCATCCATGAAAC-3' and antisense: 5'-TAAAACGCAGCTCAGTAACAGTCCG-3') were used to generate 180 bp and 348 bp PCR products, respectively. After electrophoresis migration on 2% agarose gel, amplicon intensity was quantified using a laser scanner densitometer (Vilber Lourmat, Marnes-la Vallée, France).
Flow cytometry
Cells were incubated with the indicated antibody at 4°C for 45 min in PBS containing 0.1% sodium azide and 5% normal rat serum to block non-specific binding and then subjected to flow cytometry analysis on an Epics XL instrument (Coulter, Roissy, France). The following antibodies directly conjugated to fluorochromes (PharMingen, Le Pont de Claix, France) were used: anti-I-A q,s,v , anti-B7-1, anti-B7-2 and isotype controls.
Antigen-presentation assay
Transduced macrophages (5 × 10 4 cells/well) were cocultured with a CII-specific T cell hybridoma (10 5 cells/well) in the presence of 40 g/ml of CII for 24 h at 37°C. 27 Culture supernatants were then collected and tested for their ability to support CTLL-2 proliferation assayed by 3 H-thymidine incorporation as described above.
Assay for homing of macrophages in arthritic mice DBA/1 mice were immunized with CII in CFA and observed until they develop CIA. Severely affected mice were selected for the homing studies. Syngeneic bone marrow-derived macrophages were labeled with the PKH67-GL green fluorescent cell linker (Sigma) according to the manufacturer's instructions and injected (2-7 × 10 6 cells) i.v. into arthritic mice. At varying times after cell transfer, tissues from the joints or other control organs (liver, lung) were collected and digested with colGene Therapy lagenase. Dissociated cells were then subjected to flow cytometry analysis and percentages of fluorescent cells were determined. Since arthritic synovial cells were shown to exhibit strong intrinsic autofluorescence, 39 tissues (n = 26) from uninjected arthritic mice were used as controls and average control percentages were calculated in each experiment. Results were expressed as incidence of joints exhibiting fluorescent cell percentages over control values.
Statistical analysis
Results were expressed as means ± s.e.m. Statistical differences between experimental and control groups were performed using the Mann-Whitney U test.
